JP2011518153A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518153A5
JP2011518153A5 JP2011504974A JP2011504974A JP2011518153A5 JP 2011518153 A5 JP2011518153 A5 JP 2011518153A5 JP 2011504974 A JP2011504974 A JP 2011504974A JP 2011504974 A JP2011504974 A JP 2011504974A JP 2011518153 A5 JP2011518153 A5 JP 2011518153A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
week
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011504974A
Other languages
English (en)
Other versions
JP5479453B2 (ja
JP2011518153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/005104 external-priority patent/WO2009128805A1/en
Publication of JP2011518153A publication Critical patent/JP2011518153A/ja
Publication of JP2011518153A5 publication Critical patent/JP2011518153A5/ja
Application granted granted Critical
Publication of JP5479453B2 publication Critical patent/JP5479453B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. 糸分裂攪乱物質/ポロ様キナーゼ(Plk)経路阻害剤を含有する、ヌクレオチド類縁化学療法剤による治療に感受性がある癌を治療するため医薬組成物
  2. 癌が、ヌクレオチド類縁化学療法剤に耐性の腫瘍、ゲムシタビン耐性癌、白血病、リンパ腫、結腸直腸癌、膵臓癌、肺癌、乳癌、卵巣癌、基底細胞癌、膀胱癌、肝臓癌、前立腺癌、胃癌、腎臓癌、メラノーマ、神経膠腫、食道癌、子宮頸癌、及び骨髄異形成症候群よりなる群から選ばれる、請求項1に記載の医薬組成物
  3. ヌクレオチド類縁化学療法剤及び有糸分裂攪乱物質/Plk経路阻害剤を含有してなる、医薬組成物。
  4. 有糸分裂攪乱物質/Plk経路阻害剤が、Plk1阻害剤を含有してなる、請求項1〜の何れか一項に記載の医薬組成物
  5. 有糸分裂攪乱物質/Plk経路阻害剤が、ON01910又はそれらの誘導体を含有してなる、請求項1〜の何れか一項に記載の医薬組成物
  6. 医薬組成物が、ON01910−Na又はそれらの誘導体を50mg/m/week〜5000mg/m/weekの用量で投与するために製剤化されている、請求項に記載の医薬組成物
  7. ヌクレオチド類縁化学療法剤が、クラドリビン、クロファラビン、フルダラビン、メルカプトプリン、ペントスタチン、チオグアニン、カペシタビン、シタラビン、デシタビン、フルオロウラシル、フロクスウリジン、サパシタビン、及びゲムシタビンよりなる群から選ばれる、請求項1〜の何れか一項に記載の医薬組成物
  8. ヌクレオチド類縁化学療法剤がゲムシタビンである、請求項に記載の医薬組成物
  9. 医薬組成物が、ゲムシタビンを500mg/m/week〜1500mg/m/weekの用量で投与するために製剤化されている、請求項に記載の医薬組成物
JP2011504974A 2008-04-17 2008-04-17 ON01910.Naは薬剤耐性腫瘍において化学療法剤活性を増強する Expired - Fee Related JP5479453B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/005104 WO2009128805A1 (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Publications (3)

Publication Number Publication Date
JP2011518153A JP2011518153A (ja) 2011-06-23
JP2011518153A5 true JP2011518153A5 (ja) 2011-08-04
JP5479453B2 JP5479453B2 (ja) 2014-04-23

Family

ID=41199352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011504974A Expired - Fee Related JP5479453B2 (ja) 2008-04-17 2008-04-17 ON01910.Naは薬剤耐性腫瘍において化学療法剤活性を増強する

Country Status (10)

Country Link
US (2) US8962614B2 (ja)
EP (1) EP2271339A4 (ja)
JP (1) JP5479453B2 (ja)
KR (1) KR101707669B1 (ja)
CN (1) CN102056607B (ja)
AU (1) AU2008354754B2 (ja)
CA (1) CA2721722C (ja)
NZ (1) NZ588749A (ja)
RU (1) RU2476239C2 (ja)
WO (1) WO2009128805A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009128805A1 (en) * 2008-04-17 2009-10-22 The Johns Hopkins University On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors
US10576050B2 (en) * 2012-12-07 2020-03-03 Onconova Therapeutics, Inc. Methods and compositions for treatment of cancer
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
ES2836772T3 (es) 2014-04-30 2021-06-28 Fujifilm Corp Composición liposomal y método para producirla
CN113633656A (zh) 2015-02-25 2021-11-12 柏业公司 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN109232403A (zh) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 作为蛋白激酶抑制剂的酰胺类前药衍生物
EP4048284A4 (en) * 2019-10-21 2023-11-01 Acura Nanomedicine Corporation METHOD FOR TREATING CANCER
WO2023158514A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US7037906B1 (en) 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070197538A1 (en) 2004-10-07 2007-08-23 Mark Nesbit Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
TW200621240A (en) * 2004-11-05 2006-07-01 Salmedix Inc Cancer treatments
CA2593523C (en) 2005-01-05 2014-04-08 Temple University - Of The Commonwealth System Of Higher Education Treatment of drug-resistant proliferative disorders
US7504513B2 (en) * 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
JP5528806B2 (ja) * 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US20080279874A1 (en) * 2007-05-07 2008-11-13 Wyeth Compositions and methods for modulation of plk1 kinase activity
WO2009128805A1 (en) * 2008-04-17 2009-10-22 The Johns Hopkins University On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Similar Documents

Publication Publication Date Title
JP2011518153A5 (ja)
Hu et al. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
JP2014177455A5 (ja)
IL264288A (en) Methods and preparations for regulating expression of apolipoprotein(a)
JP2018126141A5 (ja)
Peters Novel developments in the use of antimetabolites
NZ602833A (en) Oral formulations of cytidine analogs and methods of use thereof
PH12015502273A1 (en) Substituted nucleosides, nucleotides and analogs thereof
HRP20120419T1 (hr) Fluoro deoksitetrahidrouridini kao inhibitori citidin deaminaze
JP2016501513A5 (ja)
PH12014502094A1 (en) Substituted nucleosides, nucleotides and analogs thereof
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
GEP201706793B (en) Substituted nucleosides, nucleotides and analogs thereof
JP2011501962A5 (ja)
JP2014521310A5 (ja)
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
Valenzuela et al. Antimetabolite treatment for pancreatic cancer
JP2019536767A5 (ja)
Yang et al. A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine
JP2009505991A5 (ja)
Hosokawa et al. Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine
JP2017516827A5 (ja)
Zhang et al. Quercetin downregulates the expression of IL15 in cancer cells through DNA methylation.
TWI615145B (zh) 含伊立替康鹽酸鹽水合物之抗腫瘤劑
JP2007513202A5 (ja)